.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,981,103

« Back to Dashboard

Claims for Patent: 8,981,103

Title:Stable crystal of 4-oxoquinoline compound
Abstract: Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractometry.
Inventor(s): Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Application Number:12/538,694
Patent Claims: 1. A crystal form of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, having an X-ray powder diffraction pattern comprising a characteristic diffraction peak at 8.54.+-.0.2.degree. .crclbar..

2. The crystal form of claim 1, having an X-ray powder diffraction pattern comprising a characteristic diffraction peak at 8.54.+-.0.1.degree. 2.crclbar..

3. The crystal form of claim 1, having an X-ray powder diffraction pattern comprising a characteristic diffraction peak at 8.54.+-.0.06.degree. 2.crclbar..

4. The crystal form of claim 1, having an X-ray powder diffraction pattern further comprising a characteristic diffraction peak at 17.24.degree..+-.0.2.degree. 2.crclbar..

5. The crystal form of claim 2, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.1.degree. and 17.24.degree..+-.0.1.degree. 2.crclbar..

6. The crystal form of claim 3, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.06.degree. and 17.24.degree..+-.0.06.degree. 2.crclbar..

7. The crystal form of claim 4, having an X-ray powder diffraction pattern further comprising a characteristic diffraction peak at 14.02.+-.0.2.degree., 2.crclbar..

8. The crystal form of claim 5, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.1.degree., 14.02.+-.0.1.degree., and 17.24.+-.0.1.degree. 2.crclbar..

9. The crystal form of claim 7, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.06.degree., 14.02.+-.0.06.degree., and 17.24.+-.0.06.degree. 2.crclbar..

10. A crystal form of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.2.degree., 14.02.+-.0.2.degree., 15.8.+-.0.2.degree., 17.06.+-.0.2.degree., 17.24.+-.0.2.degree., 24.16.+-.0.2.degree., and 25.74.+-.0.2.degree. 2.crclbar..

11. The crystal form of claim 10, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.1.degree., 14.02.+-.0.1.degree., 15.68.+-.0.1.degree., 17.24.+-.0.1.degree., 24.16.+-.0.1.degree., and 25.74.+-.0.1.degree. 2.crclbar..

12. The crystal form of claim 10, having an X-ray powder diffraction pattern comprising characteristic diffraction peaks at 8.54.+-.0.06.degree., 14.02.+-.0.06.degree., 15.68.+-.0.06.degree., 17.06.+-.0.06.degree., 17.24.+-.0.06.degree., 24.16.+-.0.06.degree., and 25.74.+-.0.06.degree. 2.crclbar..

13. Crystal form III of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid having an X-ray powder diffraction pattern as shown in FIG. 1.

14. The crystal form of any one of claims 1 and 2 to 13 having a purity of crystal of not less than 70%.

15. The crystal form of any one of claims 1 and 2 to 13 having a purity of crystal of not less than 80%.

16. The crystal form of any one of claims 1 and 2 to 13 having a purity of crystal of not less than 90%.

17. The crystal form of any one of claims 1 and 2 to 13 having a purity of crystal of not less than 95%.

18. The crystal form of any one of claims 1 and 2 to 13 having a purity of crystal of not less than 98%.

19. A pharmaceutical composition comprising the crystal form of any one of claims 1 and 2 to 13 and a pharmaceutically acceptable carrier.

20. The pharmaceutical comppsition of claim 19 wherein the composition is in the form of a tablet, pill, powder or granule.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc